Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease

Abdelrahman, Basma A.; El-Khatib, Aiman S.; Attia, Yasmeen M.

doi:10.1016/j.lfs.2023.122124

Cited by 4 publications

(1 citation statement)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noteworthy is the role of vitamin D in metabolic alterations (e.g., obesity and type 2 diabetes), which are highly involved in the onset and development of cardiovascular (CV) disease; indeed, low vitamin D levels have been associated with type 2 diabetes and obesity, whereas vitamin D supplementation may improve glycemic control in type 2 diabetes patients, as well as insulin secretion and sensitivity [7,8]. Additionally, results obtained from several studies highlight not only the association between nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, and vitamin D deficiency but also suggest that vitamin D supplementation may be beneficial in NAFLD (e.g., improving intestinal permeability, as well as intestinal microbial metabolites, hepatic inflammation, and liver fibrosis) [9,10].…”

Section: Introductionmentioning

confidence: 99%

Interplay between Vitamin D and Sphingolipids in Cardiometabolic Diseases

Fenizia,

Gaggini,

Vassalle

2023

IJMS

View full text Add to dashboard Cite

Sphingolipids (SLs) are structural, bioactive molecules with several key cellular roles, whereas 1,25-dihydroxyvitamin D (1,25(OH)D), the active form of vitamin D, is considered the major regulator of calcium homeostasis, although it also exerts other extraskeletal effects. Many studies reported the physiological connection between vitamin D and SLs, highlighting not only the effects of vitamin D on SL metabolism and signaling but also the influence of SLs on vitamin D levels and function, thus strongly suggesting a crosstalk between these molecules. After a brief description of 1,25(OH)D and SL metabolism, this review aims to discuss the preclinical and clinical evidence on the crosstalk between SLs and 1,25(OH)D, with a special focus on cardiometabolic diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Interplay between Vitamin D and Sphingolipids in Cardiometabolic Diseases

Fenizia,

Gaggini,

Vassalle

2023

IJMS

View full text Add to dashboard Cite

show abstract

The role of body mass index in the association between serum vitamin D and non-alcoholic fatty liver disease: A mediation analysis

Han,

Liu,

Guo

et al. 2024

Journal of Functional Foods

View full text Add to dashboard Cite

Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights

Aggeletopoulou,

Tsounis,

Triantos

2024

IJMS

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly prevalent condition characterized by abnormal fat accumulation in the liver, often associated with metabolic disorders. Emerging evidence suggests a potential link between vitamin D deficiency and the development and progression of MASLD. The current review provides a concise overview of recent studies uncovering novel mechanistic insights into the interplay between vitamin D and MASLD. Several epidemiological studies have highlighted a significant association between low vitamin D levels and an increased risk of MASLD. Vitamin D, traditionally known for its role in bone health, has now been recognized as a key player in various physiological processes, including immune regulation and inflammation. Experimental studies using animal models have demonstrated that vitamin D deficiency exacerbates liver steatosis and inflammation, suggesting a potential protective role against MASLD. Mechanistically, vitamin D appears to modulate MASLD through multiple pathways. Firstly, the vitamin D receptor (VDR) is abundantly expressed in liver cells, indicating a direct regulatory role in hepatic function. Activation of the VDR has been shown to suppress hepatic lipid accumulation and inflammation, providing a mechanistic basis for the observed protective effects. Additionally, vitamin D influences insulin sensitivity, a critical factor in MASLD pathogenesis. Improved insulin sensitivity may mitigate the excessive accumulation of fat in the liver, thus attenuating MASLD progression. In parallel, vitamin D exhibits anti-inflammatory properties by inhibiting pro-inflammatory cytokines implicated in MASLD pathophysiology. Experimental evidence suggests that the immunomodulatory effects of vitamin D extend to the liver, reducing inflammation and oxidative stress, key drivers of MASLD, and the likelihood of hepatocyte injury and fibrosis. Understanding the complex interplay between vitamin D and MASLD provides a basis for exploring targeted therapeutic strategies and preventive interventions. As vitamin D deficiency is a modifiable risk factor, addressing this nutritional concern may prove beneficial in mitigating the burden of MASLD and associated metabolic disorders.

show abstract

Insights into the role of vitamin D in targeting the culprits of non-alcoholic fatty liver disease

Cited by 4 publications

References 182 publications

Interplay between Vitamin D and Sphingolipids in Cardiometabolic Diseases

Interplay between Vitamin D and Sphingolipids in Cardiometabolic Diseases

The role of body mass index in the association between serum vitamin D and non-alcoholic fatty liver disease: A mediation analysis

Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights

Contact Info

Product

Resources

About